Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce S Plested

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
The Journal of Infection|February 15, 2024
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccinesRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
Microorganisms|November 27, 2024
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza VaccineTimothy S Vincent, Mingzhu Zhu, Anand Parekh, et al.
The Journal of Infection|January 28, 2025
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trialChijioke Bennett, Gordon Chau, Erika Clayton, et al.
The Lancet. Infectious Diseases|September 26, 2021
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trialVivek Shinde, Iksung Cho, Joyce S Plested, et al.
JAMA Network Open|April 26, 2023
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical TrialGermán Áñez, Lisa M Dunkle, Cynthia L Gay, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2022
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialGermán Áñez, Lisa M Dunkle, Cynthia L Gay, et al.
The Lancet. Respiratory Medicine|November 20, 2021
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trialSeth Toback, Eva Galiza, Catherine Cosgrove, et al.
The Journal of Infection|June 28, 2025
Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform-specific priming and immune imprintingRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
Vaccine|June 6, 2025
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19)Germán Áñez, Alice McGarry, Wayne Woo, et al.
The Lancet. Infectious Diseases|August 13, 2022
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialRaburn M Mallory, Neil Formica, Susan Pfeiffer, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
The Journal of Infection|February 15, 2024
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccinesRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
Microorganisms|November 27, 2024
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza VaccineTimothy S Vincent, Mingzhu Zhu, Anand Parekh, et al.
The Journal of Infection|January 28, 2025
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trialChijioke Bennett, Gordon Chau, Erika Clayton, et al.
The Lancet. Infectious Diseases|September 26, 2021
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trialVivek Shinde, Iksung Cho, Joyce S Plested, et al.
JAMA Network Open|April 26, 2023
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical TrialGermán Áñez, Lisa M Dunkle, Cynthia L Gay, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2022
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialGermán Áñez, Lisa M Dunkle, Cynthia L Gay, et al.
The Lancet. Respiratory Medicine|November 20, 2021
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trialSeth Toback, Eva Galiza, Catherine Cosgrove, et al.
The Journal of Infection|June 28, 2025
Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform-specific priming and immune imprintingRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
Vaccine|June 6, 2025
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19)Germán Áñez, Alice McGarry, Wayne Woo, et al.
The Lancet. Infectious Diseases|August 13, 2022
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialRaburn M Mallory, Neil Formica, Susan Pfeiffer, et al.
Pageof 5